Abstract: A system and method for identifying and tracking singly conveyed products, which are cylindrical at least in regions, and have a peripheral surface to which a marking is respectively applied. The products are conveyed in a direction of transport by a transport device, and during conveyance are rotated by a friction element that comes into engagement with each product by friction as the products are being conveyed. The marking applied to the peripheral surface of each product is read by a stationary camera system having at least two cameras, as the respective product is being rotated.

Abstract: The present invention provides methods of treating a subject with non-alcoholic fatty liver disease (NAFLD), insulin resistance, obesity or hyperlipidemia, comprising administering to the subject an effective amount of a compound according to Formula I: or a physiologically acceptable salt thereof.

Abstract: An alteration in phosphorylation of serine 105, within the activation domain of NF-IL6/LAP, alters its transcriptional efficacy. Polypeptides, polynucleotides and methods of use for modified transcriptional activators allow regulation of gene expression.

Abstract: An alteration in phosphorylation of serine 105, within the actvation domain of NF-IL6/LAP, alters its transcriptional efficacy. Potypeptides, polynucleotides and methods of use for modified transcriptional activators allow regulation of gene expression.

Abstract: Disclosed are viral variants exhibiting reduced sensitivity to particular agents including nucleoside analogues and immunological mediators such as immunoglobulins and immune cells. Also provided are hepatitis B virus (HBV) variants which exhibit a level of replication fitness in the presence of a nucleoside analogue similar to or greater than in the absence of the nucleoside analogue. The present invention also provides methods of treating HBV infection, including a method for identifying a need to change or otherwise alter an existing therapeutic regimen. Also disclosed are methods for monitoring the development in a subject of an increased HBV load in the presence of a nucleoside analogue. The present invention further provides the use of nucleoside analogue-resistant HBV variants which exhibit a similar or increased replication fitness in the presence of the nucleoside analogue compared to in the absence of the nucleoside analogue to screen for medicaments to treat HBV infection.

Abstract: An alteration in phosphorylation of serine 105, within the activation domain of NF-IL6/LAP, alters its transcriptional efficacy. Polypeptides, polynucleotides and methods of use for modified transcriptional activators allow regulation of gene expression.